Navigation Links
Thomson Reuters Publishes Pharma Matters White Paper, 'The Five Myths of Generic Competition'
Date:3/10/2009

Unique Survey Shows Much Room for Originator Pharmaceutical Companies to Improve Their Understanding of Generic Competition

PHILADELPHIA and LONDON, March 11 /PRNewswire/ -- The Healthcare and Science business of Thomson Reuters today released the white paper, "The Five Myths of Generic Competition," highlighting what originator pharmaceutical and biotech companies can do to improve their forecasting of the likely timing, source and intensity of competition from generic drugs.

The findings in this white paper are based on an independent survey of commercial professionals in pharmaceutical and biotech companies. The research was conducted by Thomson Reuters during May and June 2008.

The survey highlights a number of prevailing attitudes among commercial professionals, including:

  • Commercial professionals believe that little can be done to prevent sales erosion by generic drugs.
  • Commercial professionals feel that originator companies have little time or resources to devote to understanding generic competition.
  • Most executives surveyed assume that such research is already being conducted by someone else in their organization.

"The intelligence gathered and analyzed by our researchers tells us that these attitudes are based on some false assumptions," says Claude Basset, VP Specialty Markets, Thomson Reuters. "Understanding and forecasting generic competition remains undoubtedly a serious strategic challenge for anyone with a brand product on the market. It's clear, however, that there is more originators could do better - and earlier - to prepare for generic competition."

In analyzing the study findings, Thomson Reuters offers guidance on when and how best to improve competitive intelligence processes by focusing on more effective sources of long-range signals, and by providing brand teams with the resources and tools necessary to better understand generic competition.

To learn more about how companies can improve their understanding and forecasting of generic competition, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/generic_myths.pdf

"The Five Myths of Generic Competition" is part of Pharma Matters, a quarterly report series from Thomson Reuters that covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Newport Vision Premium(TM), Thomson Pharma(R), and the Thomson Messaging Mapping System(SM).

To sign up for the Thomson Reuters Pharma Matters series of publications visit:

http://scientific.thomsonreuters.com/info/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Reuters Study Tracks Impact of Recession on Hospitals
2. VHA Selects Clinical Xpert from Thomson Reuters as its Preferred Solution for Mobile Clinical Improvement Systems
3. Molecular Oncology accepted into Thomson Reuters index
4. Thomson Reuters Releases 2009 Patent Focus Report
5. Kids and Their Families Are Hit Hardest During Flu Season, According to Thomson Reuters Study
6. Thomson Reuters Launches Liquent PublishPerfect(TM)
7. CMS Selects Thomson Reuters to Help Implement Medicare Medical Home Demonstration Project for Medicare Recipients
8. Thomson Reuters Installs Clinical Xpert at Catholic Healthcare West for HIS Downtime Solution
9. Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
10. Tomball Regional Medical Center Selects Clinical Xpert(TM) from Thomson Reuters to Lead Quality Improvement Initiatives
11. Thomson Reuters White Paper Explores the Role of Biomarkers in Clinical Trials and Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... ... physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were submitted ... managing the award process. Results were announced the magazine’s January 2017 issue ...
(Date:1/14/2017)... ... 14, 2017 , ... Healthy living brand Moody Zook recently ... products. With more and more people opting to go organic in their lifestyle, ... cater to specific needs. , Moody Zook focused particularly on their newly launched ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... sugar levels. Counting carbohydrates is as easy as checking the nutrition label on ... affects blood sugar levels. Despite being sugar-free, proteins can influence — either positively ...
(Date:1/13/2017)... ... January 13, 2017 , ... With the increasing public preference ... providing additional organic alternatives for customers who have grown more conscious about maintaining ... of all-natural activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained ...
(Date:1/13/2017)... ... ... "We wanted to create a design for orthodontic appliances that would make ... Beach, Va. , They created a prototype for the patent-pending BRACE FACERS to add ... be customized to suit personal tastes. They can be used to create custom designs ...
Breaking Medicine News(10 mins):
(Date:1/13/2017)... January 13, 2017 Constant research ongoing ... will collectively contribute to the demand for western blotting technique. ... value of US$ 551.0 Mn by 2016 end. Developing economies ... most lucrative markets for western blotting, whereas North ... ...
(Date:1/13/2017)... NEW YORK , January 13, 2017 ... Biotech equities to see how they have fared at ... CLVS ), Galena Biopharma Inc. (NASDAQ: GALE ... ). These companies harness cellular and biomolecular processes to ... diseases, reduce our environmental footprint, feed the hungry, use ...
(Date:1/13/2017)... 2017   JDRF , the leading global ... pleased to announce that after more than a ... & Medicaid Services (CMS) has recognized continuous glucose ... use in making diabetes treatment decisions as durable ... eligible for coverage under Medicare. JDRF has been ...
Breaking Medicine Technology: